AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,503 | $1,024 | $664 | $867 |
| - Cash | $83 | $92 | $159 | $156 |
| + Debt | $137 | $142 | $68 | $65 |
| Enterprise Value | $1,557 | $1,074 | $572 | $776 |
| Revenue | $9 | $17 | $4 | $5 |
| % Growth | -47.6% | 303.4% | -16.1% | – |
| Gross Profit | $9 | $10 | $4 | $5 |
| % Margin | 100% | 58.7% | 100% | 100% |
| EBITDA | -$40 | -$39 | -$52 | -$55 |
| % Margin | -449.2% | -227.3% | -1,225.5% | -1,095.3% |
| Net Income | -$57 | -$35 | -$46 | -$34 |
| % Margin | -637.8% | -203.3% | -1,077.2% | -677.4% |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 |
| % Growth | -58.3% | 20% | -25% | – |
| Operating Cash Flow | -$53 | -$32 | -$12 | -$8 |
| Capital Expenditures | -$9 | -$13 | -$11 | -$16 |
| Free Cash Flow | -$62 | -$46 | -$22 | -$24 |